As suggested in recent studies, genetic subtyping-guided R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens and the addition of various drugs [i.e., Bruton’s tyrosine kinase inhibitors (BTKi), lenalidomide] to R-CHOP (termed R-CHOP+X) have improved the outcome of DLBCL (19, 20). This evidence concerns the gene IBTK and diffuse large B-cell lymphoma.